CONCORD, Calif.--(BUSINESS WIRE)--June 26, 2007--Cerus Corporation
(NASDAQ:CERS) announced today that company management will host an
investment community conference call beginning at 4:30 p.m. EST on
Tuesday, June 26, 2007, to discuss the French tender award announced
earlier today and other corporate news. To access the webcast via the internet, log on to www.cerus.com.
Please connect to the company's website at least 15 minutes prior to
the conference call to ensure adequate time for any software
downloads. Alternatively, you may access the live conference call by
dialing 800-510-0219 (U.S.) or 617-614-3451 (International) and dial
participant passcode 92481931. A telephone replay will be available
approximately two hours after the call through 5:00 p.m. EST, July 3,
2007. To access the replay, please call 888-286-8010 (U.S.) or
617-801-6888 and enter passcode 98235978. The webcast will be archived
on www.cerus.com through July 3, 2007. ABOUT CERUS Cerus Corporation is a biopharmaceutical company that develops and
commercializes novel, proprietary products in the fields of blood
safety and immunotherapy designed to provide safer, more effective
medical options to patients in areas of substantial unmet medical
needs. In the field of blood safety, the company is developing and
commercializing the INTERCEPT Blood System, which is based on the
company's proprietary Helinx technology. The system is designed to
enhance the safety of donated blood components by inactivating
viruses, bacteria, parasites and other pathogens, as well as
potentially harmful white blood cells. In the field of immunotherapy,
the company is employing its proprietary attenuated Listeria vaccine
platform to develop a series of novel therapies to treat cancer, and
it is applying its proprietary Killed But Metabolically Active
technology platform in the research and development of prophylactic
and therapeutic vaccines for infectious diseases. INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of
Cerus Corporation.
CONTACT: Cerus Corporation
Myesha Edwards, 925-288-6017
Corporate Communications & Investor Relations SOURCE: Cerus Corporation
|